From the European Society for Medical Oncology 2012 Congress: Additional safety, tolerability data for tivozanib versus sorafenib in metastatic RCC shows fewer adverse events

New data demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first-line setting for patients with metastatic renal cell carcinoma (RCC), was presented at ESMO's 2012 Congress.